Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.38 |
| ▸ | FEN1 | P39748 | 5/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654167 | 0.81 | IDO1 (0.41) | GRM5NPC1RAB9AKDM4EALOX5AP | |
| SCHEMBL30462006 | 0.77 | USP1 (0.46) | GRM5ALOX5APFEN1 | |
| SCHEMBL26627854 | 0.77 | USP1 (0.46) | GRM5ALOX5APFEN1 | |
| SCHEMBL30707897 | 0.74 | USP1 (0.37) | GRM5ALOX5APFEN1 | |
| SCHEMBL30278074 | 0.72 | PIK3CD (0.41) | — | |
| SCHEMBL16692863 | 0.72 | GRM5 (0.40) | GRM5RAB9AMAPTKDM4EPOLB | |
| SCHEMBL30698015 | 0.72 | GRM5 (0.40) | GRM5MAPTALOX5APFEN1 | |
| SCHEMBL30698038 | 0.72 | GRM5 (0.40) | GRM5MAPTALOX5APFEN1 | |
| SCHEMBL12654074 | 0.72 | GRM5 (0.40) | GRM5MAPTKDM4EALOX5APFEN1 | |
| SCHEMBL16692822 | 0.72 | GRM5 (0.40) | GRM5MAPTALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833831-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060161001-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006069258-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161001-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | GRM5 2068/4885HTR2C 860/4885NPC1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.